Details for Patent: 10,836,768

Which drugs does patent 10,836,768 protect, and when does it expire?

Patent 10,836,768 protects VEOZAH and is included in one NDA.

This patent has forty-four patent family members in thirty-one countries.

Summary for Patent: 10,836,768

Title:	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Abstract:	A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
Inventor(s):	Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
Assignee:	Ogeda SA
Application Number:	US16/204,390
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,836,768

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	10,836,768					TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE

International Family Members for US Patent 10,836,768

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2948455		301272	Netherlands
European Patent Office	2948455		CA 2024 00017	Denmark
European Patent Office	2948455		CR 2024 00017	Denmark
European Patent Office	2948455		PA2024513	Lithuania
European Patent Office	2948455		LUC00342	Luxembourg
European Patent Office	2948455		2024C/523	Belgium